Search Results 361-370 of 18020 for Alopecia

  1. Clinical trials - Oncology (Medical)

    Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...

  2. Study of Magrolimab Combination Therapy to Treat Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer - Mayo Clinic

    previously administered agent. - Note: individuals with any grade neuropathy or alopecia are an exception to this criterion and will qualify for the study ...

  3. 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer - Mayo Clinic

    toxicities related to prior therapies (i.e. prior chemotherapy, radiation, etc.) except alopecia 11. Participants must have adequate organ function: - Bone ...

  4. Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome - Mayo Clinic

    Subjects with vitiligo or alopecia;; Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement;; Subjects with psoriasis ...

  5. An Expanded Access Study of Iniparib Combined with Gemcitabine and Carboplatin for the Treatment of Breast Cancer - Mayo Clinic

    ... alopecia, related to anticancer therapy prior to the first dose of study drug; Major medical conditions that might affect EAP participation (e.g. ...

  6. Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma - Mayo Clinic

    Patients must have recovered sufficiently from all acute adverse effects of prior therapies, excluding alopecia. Patients must have an ECOG performance ...

  7. A Study of the Combination of IMCgp100 with Durvalumab and/or Tremelimumab for Patients with Advanced Cutaneous Melanoma - Mayo Clinic

    ... alopecia, peripheral neuropathy and ototoxicity, which are excluded if ≥ NCI CTCAE grade 3) due to prior cancer therapy; Chronic systemic corticosteroid use ...

  8. A Study of ASTX660 Alone or Combined with ASTX727 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) - Mayo Clinic

    ... alopecia). Hypersensitivity to decitabine, ASTX727, ASTX660, or any of their excipients. Liver cirrhosis, or chronic liver disease Child-Pugh Class B or C ...

  9. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

    Ongoing toxic manifestations of previous treatments > Grade 2 with the exception of alopecia and neuropathy. Subjects with treated brain metastases with ...

  10. KO-2806 Monotherapy And Combination Therapies In Advanced Solid Tumors - Mayo Clinic

    * Toxicity (excluding alopecia) from prior therapy that has not been completely resolved to baseline at the time of consent. * Active or prior documented ...